Evaluation of the Effect of Phosphodiesterase Inhibitors on Mortality in Chronic Heart Failure Patients. A Meta-analysis

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1994 Jan 1

PMID 8070498

Citations 21

Authors

P Nony

J P Boissel

M Lievre

A Leizorovicz

M C Haugh

S Fareh

B de Breyne

Affiliations

Soon will be listed here.

Abstract

We examined the influence of phosphodiesterase inhibitors (PDIs) on mortality in patients with overt chronic heart failure. A total of 13 randomised, placebo-controlled trials of PDIs involving 2808 patients were selected. Meta-analysis, using data for all patients, showed that there was a non-significant (P = 0.16) increase of about 17% in the mortality rate of patients receiving a PDI [odds ratio (OR) 1.17, 95% confidence interval (CI) 0.94-1.46]. However, the observed treatment effects were found to be heterogeneous due to the results from the trials on vesnarinone. The heterogeneity became non-significant (P = 0.77) when these trials were removed, and a significant increase in the mortality rate was observed under treatment with the other PDIs (OR 1.41, 95% CI 1.11-1.79). In the subgroups of patients with or without additional vasodilator (VD) treatment, similar results were observed (PDI with VD: OR 1.3, 95% CI 1.03-1.7; PDI without VD: OR 2.04, 95% CI 1.1-3.8). These results indicate that PDIs (with the exception of vesnarinone) should not be prescribed for long-term use in patients with overt chronic heart failure. Additional vasodilator treatment in patients receiving PDIs for chronic heart failure does not explain the increased mortality seen with PDIs. This toxicity must, therefore, arise by other mechanisms. Further experimental and clinical evaluation is needed to confirm the beneficial influence of vesnarinone on survival in chronic heart failure patients and to identify the mechanism(s) differentiating this agent's therapeutic effect from that of other PDIs.

Citing Articles

Physiological effects of ivabradine in heart failure and beyond.

Iness A, Shah K, Kukreja R Mol Cell Biochem. 2023; 479(9):2405-2414.

PMID: 37768496 DOI: 10.1007/s11010-023-04862-5.

Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use.

Papp Z, Agostoni P, Alvarez J, Bettex D, Bouchez S, Brito D Card Fail Rev. 2020; 6:e19.

PMID: 32714567 PMC: 7374352. DOI: 10.15420/cfr.2020.03.

Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use.

Papp Z, Agostoni P, Alvarez J, Bettex D, Bouchez S, Brito D J Cardiovasc Pharmacol. 2020; 76(1):4-22.

PMID: 32639325 PMC: 7340234. DOI: 10.1097/FJC.0000000000000859.

Patient Attributes Associated With Better Long-Term Outcomes on Palliative Milrinone.

Sharma T, Balakumaran K, Tandon V, Shah N, Arora S Cureus. 2020; 12(5):e7979.

PMID: 32523836 PMC: 7273353. DOI: 10.7759/cureus.7979.

Acute isoproterenol leads to age-dependent arrhythmogenesis in guinea pigs.

Woulfe K, Wilson C, Nau S, Chau S, Phillips E, Zang S Am J Physiol Heart Circ Physiol. 2018; 315(4):H1051-H1062.

PMID: 30028197 PMC: 6230911. DOI: 10.1152/ajpheart.00061.2018.

References

. A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. OPC-8212 Multicenter Research Group. Cardiovasc Drugs Ther. 1990; 4(2):419-25. DOI: 10.1007/BF01857748. View

Simonton C, Chatterjee K, Cody R, Kubo S, Leonard D, Daly P . Milrinone in congestive heart failure: acute and chronic hemodynamic and clinical evaluation. J Am Coll Cardiol. 1985; 6(2):453-9. DOI: 10.1016/s0735-1097(85)80185-6. View

Weber K, Gill S, Janicki J, Maskin C, Jain M . Newer positive inotropic agents in the treatment of chronic cardiac failure. Current status and future directions. Drugs. 1987; 33(5):503-19. DOI: 10.2165/00003495-198733050-00005. View

Maskin C, Weber K, Janicki J . Long-term oral enoximone therapy in chronic cardiac failure. Am J Cardiol. 1987; 60(5):63C-67C. DOI: 10.1016/0002-9149(87)90528-5. View

Mulrow C, Mulrow J, Linn W, Aguilar C, Ramirez G . Relative efficacy of vasodilator therapy in chronic congestive heart failure. Implications of randomized trials. JAMA. 1988; 259(23):3422-6. View

Wood M, Hess M . Long-term oral therapy of congestive heart failure with phosphodiesterase inhibitors. Am J Med Sci. 1989; 297(2):105-13. DOI: 10.1097/00000441-198902000-00006. View

DiBianco R, Shabetai R, Kostuk W, Moran J, SCHLANT R, Wright R . A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med. 1989; 320(11):677-83. DOI: 10.1056/NEJM198903163201101. View

Assmann I, Kassel P, Duck H, FIEHRING H, Morgan P, Schmidt P . [Acute and long-term effects of pimobendan (UD-CG 115) in NYHA II and III heart failure. Results of a randomized multicenter double-blind study]. Z Kardiol. 1991; 80(11):687-94. View

DiBianco R . Acute positive inotropic intervention: the phosphodiesterase inhibitors. Am Heart J. 1991; 121(6 Pt 1):1871-5. DOI: 10.1016/0002-8703(91)90078-v. View

10.

Furberg C, Yusuf S . Effect of drug therapy on survival in chronic congestive heart failure. Am J Cardiol. 1988; 62(2):41A-45A. DOI: 10.1016/s0002-9149(88)80084-5. View

11.

Hood Jr W . Controlled and uncontrolled studies of phosphodiesterase III inhibitors in contemporary cardiovascular medicine. Am J Cardiol. 1989; 63(2):46A-53A. DOI: 10.1016/0002-9149(89)90393-7. View

12.

Peto R . Clinical trial methodology. Biomedicine. 1978; 28 Spec No:24-36. View

13.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

14.

Packer M . Vasodilator and inotropic drugs for the treatment of chronic heart failure: distinguishing hype from hope. J Am Coll Cardiol. 1988; 12(5):1299-317. DOI: 10.1016/0735-1097(88)92615-0. View

15.

. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987; 316(23):1429-35. DOI: 10.1056/NEJM198706043162301. View

16.

Busch F, Tillmann A, Becker E, OWSIANOWSKI M, Berg P . The inhibitory effects of a positive inotropic quinolinone derivative, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), on bone-marrow progenitor cells and peripheral lymphocytes. Eur J Clin Pharmacol. 1992; 42(6):629-33. DOI: 10.1007/BF00265927. View

17.

Feldman A, Bristow M, Parmley W, Carson P, Pepine C, Gilbert E . Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med. 1993; 329(3):149-55. DOI: 10.1056/NEJM199307153290301. View

18.

Curfman G . Inotropic therapy for heart failure--an unfulfilled promise. N Engl J Med. 1991; 325(21):1509-10. DOI: 10.1056/NEJM199111213252111. View

19.

Packer M, Medina N, Yushak M . Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure. Circulation. 1984; 70(6):1038-47. DOI: 10.1161/01.cir.70.6.1038. View

20.

Packer M, Carver J, Rodeheffer R, Ivanhoe R, DiBianco R, Zeldis S . Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991; 325(21):1468-75. DOI: 10.1056/NEJM199111213252103. View